HIMS Stock Falls Despite Latest Deal to Expand International Footprint

Hims & Hers (HIMS) is acquiring ZAVA, a European digital health platform with 1.3 million active customers, to expand into Germany, France, and Ireland; the deal is expected to close in H2 2025 and be accretive by 2026. Despite the strategic rationale and a projected 22.2% CAGR for the digital health market through 2030, HIMS shares fell approximately 3.6% following the announcement, though the company has historically realized synergies from acquisitions and boasts a 154.1% share price increase over the past year.

Analysis

Hims & Hers Health, Inc. (HIMS) announced a strategic agreement to acquire ZAVA, a European digital health platform, marking a significant step in its global expansion strategy to enter Germany, France, and Ireland, while strengthening its U.K. presence. The transaction is anticipated to close in the second half of 2025 and is projected to be accretive to HIMS' earnings by 2026. This move aims to introduce HIMS' personalized digital health services—spanning dermatology, weight loss, sexual health, and mental health—to the European market, leveraging ZAVA's established network of over 1.3 million active customers and its medical team, which conducted nearly 2.3 million consultations in 2024. Despite the clear strategic rationale and alignment with the robust growth forecast for the global digital health market (estimated CAGR of 22.2% from 2025 to 2030), HIMS shares declined approximately 3.6% following the announcement. This short-term market reaction contrasts with HIMS' strong historical performance, including a 154.1% share price surge over the past year, a significant 66.7% earnings surprise in the last reported quarter, and a favorable 1.3% earnings yield compared to the industry's negative yield. The ZAVA acquisition complements other recent strategic moves by HIMS, such as the February acquisitions of a U.S.-based peptide facility and an at-home lab testing company, underscoring a consistent strategy of expanding capabilities and market reach.

Key Decisions for Investors

• Investors should evaluate the recent approximate 3.6% dip in HIMS stock as a potential entry point, considering the long-term strategic value of the ZAVA acquisition for European market penetration and its expected accretion by 2026.
• Monitor HIMS' progress in integrating ZAVA post the H2 2025 closing and its subsequent ability to capture market share in the new European territories, particularly given the high-growth environment of the digital health sector.
• Consider HIMS' track record of realizing synergies from previous acquisitions, its strong recent financial performance including a 66.7% earnings surprise, and its significant 154.1% share price appreciation over the past year when assessing the risk-reward profile of this international expansion.